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The oestrogen receptor (ER) is a nuclear steroid receptor that upon
activation by its ligands (e.g. oestrogen) initiates a cascade of
events resulting in increased cellular proliferation in its target
tissues (Warner et al, 1999). Since oestrogen is one of the most
potent mitogens for breast cancer cells, it is no surprise that ER is
the most important target for endocrine therapy of breast cancer
(Osborne, 1998). Recently, a number of factors which regulate
nuclear hormone receptor activity have been identified. Cofactors
capable of increasing receptor action, termed coactivators, include
transcriptional intermediary factor 1 (TIF1), nuclear receptor inter-
acting protein (NRIP1), nuclear receptor coactivator 2 (TIF2),
steroid receptor coactivator 1 (SRC1), amplified in breast cancer 1
(AIB1), the cyclic AMP (cAMP)-response element binding protein
(CREB) binding protein (CBP) (Glass et al, 1997; Shibata et al,
1997) and many more. The family of corepressors (negative regula-
tors) of ER is smaller; the best characterized ones being the nuclear
receptor corepressor (N-CoR) (Horlein et al, 1995; Shibata et al,
1997) the silencing mediator of retinoid and thyroid receptors
(SMRT) (Chen and Evans, 1995; Sande and Privalsky, 1996) and
the repressor of ER activity (REA) (Montano et al, 1999). The
overexpression of coactivators or the loss of corepressors could
lead to deregulation of oestrogen-dependent pathways related to
mammary epithelial cell proliferation, and thus to breast tumorige-
nesis. And indeed, some of the ER cofactors have recently been
characterized as playing major roles in breast tumorigenesis
(Horlein et al, 1995; Anzick et al, 1997; Shibata et al, 1997). The
ER coactivator AIB1 was cloned during a search on the long arm of
chromosome 20 for genes whose expression and copy number are
elevated in human breast cancer, and subsequent analysis in 105
breast tumour specimens confirmed its overexpression (Anzick
et al, 1997). Interestingly, the breast/ovarian tumour suppressor
gene BRCA1 has recently been characterized as an ER corepressor
(Fan, 1999) again suggesting that ER coregulators are crucial in
breast tumorigenesis. Thus, it might be expected that other ER
coactivators and corepressors might play similar important roles in
breast cancer development and progression. 
The nuclear matrix protein SAFB (Renz, 1996; Oesterreich,
1997) has been shown to be an ER corepressor (Oesterreich et al,
2000). ER and SAFB interact in in-vitro binding assays
(Glutathione-S-Transferase [GST]-pulldown assays) and in cell
lines (co-immunoprecipitation experiments). In cell lines, there is
binding of SAFB to ER in the presence or absence of oestradiol;
however, binding is significantly increased by the antioestrogen
tamoxifen. Overexpression of SAFB results in repression of
oestrogen-mediated transactivation of gene expression by the ER.
Furthermore, as a result of SAFB overexpression, the antagonist
activity of tamoxifen on ER can be enhanced, and the agonist
activity of tamoxifen can be inhibited. 
These results led us to investigate whether the ER corepressor
SAFB could also be involved in breast tumorigenesis. Towards
this goal we analysed whether the chromosomal locus for SAFB is
a frequent target for chromosomal aberrations, i.e., allelic deletion.
Allelic deletion manifested as loss of heterozygosity (LOH) at
polymorphic loci is recognized as a hallmark for genes involved in
tumour suppression; thus, high LOH at the SAFB locus would
suggest that this recently identified ER cofactor could play an
important role in breast tumour suppression. In the present study
we proposed to study human breast cancer specimens for the rate
of LOH at different markers that colocalize with or are adjacent to
the SAFB locus on chromosome 19p13. To strengthen our hypo-
thesis we also performed mutational analysis of SAFB in both
LOH-positive tumours as well as in breast cancer cell lines. 
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Summary We have recently discovered that the nuclear matrix protein SAFB is an oestrogen receptor corepressor. Since it has become clear
that many steroid receptor cofactors play important roles in breast tumorigenesis, we investigated whether SAFB could also be involved in
breast cancer. To address this question, the gene locus was examined for structural alterations in breast cancer tissue. Laser capture
microdissection was used for isolating DNA from paired primary breast tumour and normal tissue specimens, and the loss of heterozygosity
(LOH) at chromosome 19p13.2–3 was determined by use of microsatellite markers. LOH was detected at the marker D19S216, which
colocalizes with the SAFB locus, in specimens from 29 (78.4%) of 37 informative patients. The peak LOH rate occurred at D19S216 near the
SAFB locus, with LOH frequencies ranging from 21.6% to 47.2% at other markers. The finding of a very high LOH rate at the marker D19S216
strongly indicates the presence of a breast tumour-suppressor gene locus. While preliminary findings of mutations in SAFB suggest that this
indeed may be a promising candidate, other potential candidate genes are located at this locus. © 2001 Cancer Research Campaign
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METHODS 
Patients, tissues, and microdissection 
The 57 patients whose tissue was evaluated in this study had
primary breast cancer; their archival paraffin-embedded tissues
were used for the analysis. For 52 of the 57 patients, a single
paraffin section yielded sufficient normal tissue (terminal duct
lobular unit) and primary cancer. For 5 patients, normal lymph
node tissues were recovered from separate blocks. Single 5 mm
sections were cut from the selected blocks, mounted on glass
slides, deparaffinized, and lightly counterstained with nuclear fast
red to guide laser capture microdissection (LCM) of cells using an
LCM instrument (Pixcell by Arcturus Engineering) (Emmert-
Buck et al, 1996; Simone et al, 1998). Briefly, a transparent thermo-
plastic film (ethylene vinyl acetate polymer) was placed over the
section on the slides. A laser directed through the microscope
optics was activated, causing the thermoplastic film to melt and
fuse with the underlying targeted cells. The selected cells
remained adherent to the film when it was removed from the slide.
An average of approximately 1000 cells (about 100 cell clusters of
10 cells each) was harvested from each tissue sample. 
LOH analysis 
LOH analysis was performed as recently described (O’Connel
et al, 1999). Briefly, DNA was prepared by a modification of the
method of Wright and Manos (Wright and Manos, 1990). The
embedded cells were incubated for 18–20 hours at 37˚C in 60 ml of
a lysis buffer that contained 10 mM Tris-HCl (pH 8.5), 1 mM
EDTA, 0.045% NP-40, 0.045% Tween-20, and 1.0 mg ml21
proteinase K. The proteinase was then inactivated at 95˚C for 10
minutes. PCR and gel electrophoresis was performed as described
previously by us (O’Connell et al, 1999). Samples were evaluated
for LOH using the microsatellite markers D19S216, D19S413,
D19S591 and D19S883. The primer pairs were obtained from
Research Genetics, Inc. (Birmingham, AL). Mapping data were
obtained from the Genome DataBase (GDBTM) at Johns Hopkins
University (Fasman et al, 1997; Talbot and Cutichia, 1999). The
intensity ratios of bands in electrophoretic gels representing
different marker alleles in the DNA obtained from paired normal
and breast cancer tissues were calculated from digitized data
collected with a storage phosphor device and analysed with the
Molecular Dynamics ImageQuant software package (Molecular
Dynamics, Sunnyvale, CA). LOH was considered positive when
the proportion ((tumour allele 1/tumour allele 2)/(normal allele
1/normal allele 2)) equalled either less than 0.71 (tumour allele 1
LOH) or greater than 1.4 (tumour allele 2 LOH). 
Mutational analysis 
RNA from MCF-7/MG (Oesterreich et al, 1993), T47D, and
MDA-MB-468 breast cancer cell lines was isolated using Qiagen
RNeasy kit (Valencia, CA) according to the manufacturer’s
instructions. First strand SAFB cDNAs were synthesized in two
parts (a 5¢ and 3¢ segment) by reverse transcriptase (RT)-PCR
using Avian Myeoblastosis Virus (AMV) RT (Promega, Madison,
WI) on 1 mg of total RNA as previously described (Wang et al,
1999). The primers for RT were 5¢-GAGTCTCTTGACTTCC-
GAGGC-3¢ (for 5¢ fragment) and 5¢-TCCAAGTACTCAG-
TAGCGGCG-3¢ (for 3¢ fragment). Multiple PCR primers were
designed to amplify overlapping regions covering the total cDNA
(see footnotes for Table 2). The amplified PCR products were
cloned using a TA cloning kit (Invitrogen, Carlsbad, CA), and
DNA was isolated and sequenced from at least two clones using
Quiaprep Miniprep kit (Quiagen, Valencia, CA). 
To analyse the genomic DNA from the LOH-positive tumours,
we have started mapping the exon/intron structure of the human
SAFB gene by PCR and sequencing. So far we have identified 10
exons, and we designed primer pairs to partially amplify three
exons (1F: 5¢ATGGCGAGAGGACGGACT-3¢ and 1R (intronic):
5¢-gcgtctggtctaaaactgagaa-3¢, product size = 271 bp; QP1F: 
5¢-GACTCTGTCAGGCCTAGGTGATTC-3¢ and QP1R: 5¢-
GCTTCATCCAACACACTGATATCC-3¢, product size 401 bp;
QP6F: 5¢-GAGCTTCCAAAAGCCAGGATCGC-3¢ and QP6R:
5¢-CGCTCCTGCTCATAGCGCAGTT-3¢, product size = 364 bp).
We analysed 11 tumours with 1F/R, 15 tumours with QP1F/R, and
2 tumours with QP6F/R. The PCR products were cleaned using
Quiaquick PCR purification kit (Quiagen), and directly sequenced.
The PCR was performed twice, and the product sequenced from
both orientations. 
Sequencing 
The sequence of cDNA was determined using an Applied
Biosystems model 310 genetic analyser. 
Statistical analysis 
The confidence intervals were calculated with the expression 1.96,
√P 3 (1–P)/i where p = the LOH frequency and i = number of
informative patients (Dawson Saunders and Trapp, 1994). 
RESULTS 
We had previously assigned SAFB to chromosome 19, band
p13.2–13.3 by fluorescent in situ hybridization (DuPont et al,
1997). This assigment was subsequently confirmed on the chromo-
some 19 radiation hybrid map (Deloukas et al, 1998), where SAFB
is positioned at 34.7 cRays. As can be seen in Table 1, additional
markers and genes have been positioned on chromosome 19p by a
combination of FISH, genetic linkage mapping (in centimorgans
or cM), and/or radiation hybrid mapping (in centirays or cR).
Based on the genetic and physical mapping of this region, 1 cM
approximates 120 kilobasepairs (kb) and 1 cR approximates 90 kb
on this map. The polymorphic marker D19S216 has been placed
on both maps (20.1 cM, 35.9 cRays), so that HET-SAF-B maps in
the D19S591-D19S216 interval just proximal to D19S216. This
region was tested for LOH using D19S216 and a series of addi-
tional markers spanning the chromosome band 19p13, namely,
D19S883 (5.5 cM), D19S591 (9.8 cM), D19S216 (20.1 cM), and
D19S413 (31.3 cM); which span 3.4 megabasepairs of DNA
(Table 1). LOH studies were carried out by comparison of normal
and primary breast cancer tissues from 57 patients. 3 of the speci-
mens showed evidence of microsatellite instability and were
excluded from further analysis. The results of this LOH study are
shown in Table 2. Marker D19S216 near SAFB showed the
highest rate of LOH (78%). Figure 1A shows a representative
example of an LOH, and Figure 1B summarizes the data from the
subset of 25 D19S216-informative patients with interstitial LOH
events. An additional 12 patients (not presented) either showed no
LOH, or showed LOH for all markers. These breakpoints can mapLOH on chromosome 19p13 495
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the smallest region of overlap for the LOH region(s). The majority
of the patients show LOH events in the 3 megabasepair region
spanning D19S591–D19S216. 4 patients (numbers 96, 179, 1086
and 1094) showed LOH events but remained heterozygous for
D19S216, indicating the tumour suppressor is distal of D19S216
(i.e, near SAFB). LOH events in 4 other patients (numbers 190,
207, 613 and 742) lost only D19S216, and patient 810 lost DNA
sequences including D19S216 and D19S413. No D19S216-
informative tumours exclusively lost D19S413. We also did not
detect any homozygous deletion. These data suggest that the
interval between D19S591–D19S216 including SAFB harbours a
tumour suppressor gene important in human breast cancer. To
support our hypothesis, mutational analysis of the remaining
SAFB allele was performed in the LOH-positive tumours. SAFB
cDNA was also sequenced in 3 breast cancer cell lines. 
First we analysed transcripts from MCF-7/MG, T47D and
MDA-MB-468 breast cancer cell lines. RT-PCR amplification
followed by subcloning of the PCR product and sequencing led to
the identification of 3 point mutations changing amino acids
(Table 3). The presence of these mutations was confirmed by
direct sequencing of genomic DNA from the cell lines (data not
shown). To further search for mutations, we PCR-amplified
genomic DNA from the nondeleted allele in the LOH-positive
tumours, and the results of this study are shown in Table 3. Two
point mutations were identified which resulted in amino acid
changes, and which were not detected in the adjacent normal
tissue. Thus, evidence from sequence analysis of SAFB suggests
that the gene indeed is a promising candidate for a breast cancer
tumour suppressor gene at the high LOH locus on chromosome
19p13. 
DISCUSSION 
Several groups have performed LOH studies on chromosome
19p13. Kerangueven et al [Kerangueven, 1997] identified
D19S216 as a marker with consistent loss (20–30% of patients) in
breast cancer using genomic DNA isolated from whole breast
tumours. Bignell et al (1998) also performed an LOH study on
chromosome 19p13.3, with the goal of analysing chromosomal
loss of the LKB1 gene (the serine/threonine kinase LKB1 is
mutated in patients with Peutz-Jeghers Syndrome, resulting in
intestinal hamartomas associated with an elevated risk for cancer).
They used the LKB-linked marker D19S565, which co-localizes
with D19S883. The Bignell study detected LOH in 7.5% of infor-
mative breast cancer specimens, as compared with 21.6% in our
study. 
It is difficult to compare the LOH rates from our present LCM-
based study to those of previous reports, since only a few studies
using LCM material have been published. For instance Bignell
et al saw 7.5% (3 of 40) LOH with D19S565 using whole tissue
genomic DNA while we found 21.6% (8 of 37) using LCM mate-
rial. Though part of this difference might simply reflect the small
number of samples, we have previously seen that LCM enriches
for tumour cells and thus always results in a higher LOH rate. As
an example, we found 53% LOH (32 of 60) at D19S216 using an
essentially identical set of manually microdissected archival
paraffin-embedded primary breast cancer specimens (data not
shown), but saw 78% LOH (29 of 37) using LCM. Brown et al
(1999) also noted elevated LOH rates at 8p12–22 in ovarian
Table 1 Markers and breast cancer candidate genes in 19p13.3 
Markera Description Genetic distance (cM)b RH distance (cR)c Megabasesd
APCL Adenomatous polyposis coli-like – 6.1 16.6+/–4.4 
D19S883 Microsatellite AFMa299yc1 5.5 22a 15.5+/–0.0 
GADD45B Growth arrest- and DNA damage-inducible gene GADD45, beta – 23.4 – 
D19S591 Microsatellite CHLC.GATA44F10 9.84 27e 15.9+/–0.0 
CDC34 Cell division cycle 34 – – 16.6+/–4.4 
SH3GL1 SH3domain, GRB2-like 1 – 32.74 16.6+/–4.4 
RANB3 RAN-binding protein 3 – 33.94 16.6+/–4.4 
SAFB Scaffold attachment factor B – 34.66 19.4+/–7.2 
D19S216 Microsatellite AFM164zb8 20.01 35.88 16.7+/–0.0 
TRIP10 Thyroid hormone receptor interactor 10 – 40.66 – 
INSR Insulin receptor 25.17 41.55 17.8 +/–0.0 
D19S413 Microsatellite AFM292wd9 32.39 59.76 18.9+/–0.0 
aGenome Database nomenclature (Talbot and Cuticchia, 1999). bDistances in centimorgans (cM) from the Marshfield Chromosome 19 Sex-Averaged linkage
map (Broman et al, 1998). cDistances in centirays (cR) from the International Radiation Hybrid Mapping Consortium (GeneMap’99) (Deloukas et al, 1998). 
dDistances from the Genome Database (Talbot and Cuticchia, 1999). eRH distances inferred based on International Radiation Hybrid Mapping Consortium
(GeneMap’99) (Deloukas et al, 1998). 
Table 2 Loss of heterozygositya frequencies for genetic markers on
chromosome 19p13.3 in breast cancer patients 
Marker Location  LOH frequency = no. of 
(centimorgans) patients with LOH / 
no. of informative patients
(%); (95% confidence 
interval)b
D19S883 5.5 8/37 (21.6); (8.3–34.9) 
D19S591 9.8 17/36 (47.2); (30.9–63.5) 
D19S216 20.1 29/37 (78.4); (65.1–91.7) 
D19S413 31.2 11/35 (31.4); (16.0–46.8) 
Heterozygosity is the presence of two different alleles for the genetic marker;
loss of heterozygosity (LOH) is present when tumour/normal allele intensities
calculated as below vary from those seen in normal tissue: LOH is present
when ((tumour allele 1/tumour allele 2)/(normal allele 1/normal allele 2)) ratio
is either equal to or less than 0.71 for tumour allele 1 or is equal to or greater
than 1.4 for tumour allele 2. bThe number of LOH events observed divided
by the subset of those patients out of the 54 tested whose normal DNA
sample was heterozygous for the genetic marker (informative cases). LOH
events cannot be detected in a patient whose normal DNA is homozygous
for the genetic marker tested. The confidence interval is calculated with the
expression 1.96 √P 3 (1–P)/i , where p = the LOH frequency and i = number
of informative patients(19). 496 S Oesterreich et al 
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cancers when comparing LCM-based LOH rates with those deter-
mined in previous allelotyping studies. Tamura et al (1994) noted
35% LOH at the retinoblastoma (RB) locus on chromosome 13
from whole tumours, but a 59% rate of RB locus LOH when the
tumour cells were enriched by flow sorting. We have also deter-
mined a rate of 56% LOH at the RB locus (data not shown) in our
LCM-based breast cancer studies. 
Our rationale for this study was that the ER corepressor SAFB
might represent a new tumour suppressor gene, and our present
finding would certainly support this hypothesis. LOH frequency
at D19S591–SAFB–D19S216 region is among the highest yet
measured in breast cancer, and mutational analysis of the SAFB
gene in both human breast cancer cell lines and tumours revealed
point mutations resulting in amino acid changes. Our sequence
analysis so far examined approximately 13% of the SAFB exon
sequence from 28 tumours. Although further sequence analysis
might lead to the identification of additional mutations in those
tumours, our preliminary results indicate that the mutation rate is
not very high. It is possible that other epigenetic changes might
play a role in inactivating SAFB. Inactivations of tumour
suppressor genes through methylation (Merlo et al, 1995; Esteller
et al, 2000; Simpson et al, 2000), through altered ubiquitin degrada-
tion (Pagano et al, 1995; Tam et al, 1997; Scheffner, 1998; Zaika
et al, 1999), and through mislocalization (Chen et al, 1995) are
increasingly recognized as alternative inactivating mechanisms.
Our own Western blot analyses have demonstrated variations in
the abundance of SAFB in breast tumour specimens – in 16% of
the tumours (10/61), no SAFB protein was detectable even after
prolonged exposure of X-ray films, and in an additional 3% (2/61),
SAFB appeared to be truncated (Townson et al, 2000). Thus, other
inactivating mechanisms might indeed be involved in loss of
SAFB. Recent studies have suggested that haploinsufficiency of
some tumour suppressor genes is sufficient for tumorigenesis
(Kairouz et al, 1999; Cook and McCaw, 2000) 
Despite these observations, we can not exclude that another
gene in close proximity to SAFB functions as a tumour suppressor
gene in human breast cancer. The 19p13 region studied spans
approximately 3 megabasepairs of DNA (see Table 1). A total of
20 known genes and 88 ESTs have been placed in this region
Table 3 SAFB cDNA and genomic DNA mutations in breast cancer cell
lines and LOH-positive tumours 
Cell line/Casea Codon Nucleotide change Amino acid change
MCF-7/MGb 1891 AAG/AGG Lys/Arg 
T47Dc 1391 CTC/CCC Leu/Pro 
MDA-MB-468d 265 AAT/GAT Asn/Asp 
Tumor #48e 1186 GCT/GTT Ala/Val 
Tumour #30e 1838 GCC/GGC Ala/Gly 
aThe complete cDNA from 3 breast cancer cell lines was analysed. The
sequence analysis of the normal/tumour DNA covers 10%, 14% and 13% of
the SAFB exon sequence from 11, 15 and 2 cases, respectively. 
bThe 3¢ first strand cDNA was amplified using forward primer 5’-GGGGTGCC-
TGTGATTAGTGT-3¢ and reverse primer 5¢- TCAGAATGGTAGCGCTCATCC3¢.
cThe 3¢ first strand cDNA was amplified using forward primer 5¢-TGGACTCTC-
TTCTACAACCAGAGC-3¢ and reverse primer 5¢- GTCACTGTTGCTCGACTT-
CTCC-3¢. dThe 5¢ first strand cDNA was amplified using forward primer
5¢-AATGGCGGAGACTCTGTCAGGC-3¢and reverse primer 
5¢-ACAGGCTGTCTGCCTTGCTC-3¢. 
eFor tumours #48 and #30, genomic DNA from microdissected tumour and
adjacent normal tissue was amplified using primer pairs 1F/1R and QP6F/6R
(see Methods). 
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Figure 1 Loss of heterozygosity (LOH) profiles in the D19S216-SAFB region. (A) DNA from microdissected tumour samples (T) and normal (N) corresponding
material was analysed by PCR using the microsatellite marker D19S216. Left: no LOH, Middle: LOH – loss of allele 1; right: LOH – loss of allele 2. (B) Bottom:
An idiogram of chromosome 19p13.11–p13.3 detailing the region of interest and the locations of the markers tested in centimorgans (cM). Top: The LOH profiles
of 25 selected patients (patient numbers: 12 to 1112) informative for D19S216 with interstitial breakpoints. Data for breast cancer patient numbers 12–1112 are
shown horizontally for each marker. Filled circles denote patients with LOH, open circles denote heterozygous patients (no LOH), and hatched circles show non-
informative patients by the International Radiation Hybrid Mapping Consortium
(GeneMap’99) (Deloukas et al, 1998). In addition to SAFB, 7
other genes in the region are potentially breast cancer related.
APCL, a homologue of the APC tumour suppressor gene, maps
near D19S883, which is outside the peak region of LOH at
D19S216. Furthermore, APCL expression has been reported to be
brain-specific (Nakagawa et al, 1999). GADD45B, a homologue
of the growth arrest and DNA damage-inducible GADD45 gene
(Sheikh et al, 2000), maps near D19S591, 800 kb from the peak of
LOH near D19S216. The thyroid hormone interacting protein
(TRIP10) (Lee et al, 1995) and the insulin receptor (INSR)
(Morris, 1997) gene appear to map distal of D19S216, and in any
case these genes seem better candidates as oncogenes rather than
tumour suppressor genes. 3 genes, the GRB2-like SH3 domain
containing gene (SH3GL1) (Giachino et al, 1997), the Ras-related
nuclear protein-binding protein (RANBP3) (Mueller et al, 1998),
and G2 cell division cycle checkpoint gene (CDC34) (Kaiser et al,
2000), all map to the same interval as SAFB. However, as noted
above, SH3GL1 seems a better candidate for an oncogene than
tumour suppressor genes. RANBP3 and CDC34 (or an uncharac-
terized EST) in this region remain potential candidate tumour
suppressor genes in addition to SAFB. 
Further studies are necessary to extensively characterize this
extremely interesting region on chromosome 19p13, and to firmly
establish SAFB as a tumour suppressor gene, or to show that a
gene other than SAFB is the true classical tumour suppressor gene
at this locus. 
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